Aromatase
inhibitors in women with increased risk of thromboembolic complications
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
There
are some patients who both significantly will benefit from antiestrogen
treatment and also, who are such high risk for thromboembolic phenomenon.
Based on what I’ve seen with aromatase inhibitors in the setting
of metastatic disease, I think its highly likely that they will
be as active if not perhaps more active than selective estrogen
receptor modulators in the adjuvant setting. So I did have a patient
who developed a deep vein thrombosis during CMF, and when it came
time to give her tamoxifen, we both opted to use the Arimidex. Again,
recognizing we’re treading into unknown territory but still
desiring to do something other than observation.
